How does emerging patent case law in the US and Europe affect precision medicine?

Mateo Aboy; Kathleen Liddell; Cristina Crespo; I Glenn Cohen; Johnathon Liddicoat; Sara Gerke; Timo Minssen

doi:10.1038/s41587-019-0265-1

How does emerging patent case law in the US and Europe affect precision medicine?

Mateo Aboy, Kathleen Liddell, Cristina Crespo, I Glenn Cohen, Johnathon Liddicoat, Sara Gerke, Timo Minssen

Laws

Research output: Contribution to journal › Article › peer-review

17 Citations (Scopus)

Original language	English
Pages (from-to)	1118-1125
Number of pages	8
Journal	Nature Biotechnology
Volume	37
Issue number	10
DOIs	https://doi.org/10.1038/s41587-019-0265-1
Publication status	Published - Oct 2019

Keywords

Algorithms
Artificial Intelligence
Biological Products
Biomarkers
Europe
Humans
Patents as Topic/legislation & jurisprudence
Precision Medicine/trends
United States

Access to Document

10.1038/s41587-019-0265-1

Cite this

@article{1518f158b86e431ead7acf97669f8756,

title = "How does emerging patent case law in the US and Europe affect precision medicine?",

keywords = "Algorithms, Artificial Intelligence, Biological Products, Biomarkers, Europe, Humans, Patents as Topic/legislation & jurisprudence, Precision Medicine/trends, United States",

author = "Mateo Aboy and Kathleen Liddell and Cristina Crespo and Cohen, {I Glenn} and Johnathon Liddicoat and Sara Gerke and Timo Minssen",

year = "2019",

month = oct,

doi = "10.1038/s41587-019-0265-1",

language = "English",

volume = "37",

pages = "1118--1125",

journal = "Nature Biotechnology",

issn = "1087-0156",